Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Group B streptococcal infection future or investigational therapies

Introduction

Overview

Overview

GBS vaccines have been investigated as a tool for reducing maternal colonization and preventing transmission to neonates;[1] however, no licensed vaccine is available currently. Phase I and II clinical trials among healthy, non-pregnant adults of monovalent polysaccharide-protein conjugate vaccines of GBS disease-associated types have shown these vaccines to be well tolerated and immunogenic.[2][3] A recent, double-blind randomized trial of a conjugate vaccine against GBS serotype III among non-pregnant women of reproductive age found a significant delay in acquisition of colonization with the vaccine-serotype among vaccine recipients.[4][5]

References

References

  1. ↑ Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL (1988). “Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus”. N Engl J Med. 319 (18): 1180–5. doi:10.1056/NEJM198811033191802. PMID 3050524.
  2. ↑ Baker CJ, Edwards MS (2003). “Group B streptococcal conjugate vaccines”. Arch Dis Child. 88 (5): 375–8. PMC 1719562. PMID 12716700.
  3. ↑ Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME; et al. (2000). “Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women”. J Infect Dis. 182 (4): 1129–38. doi:10.1086/315839. PMID 10979909.
  4. ↑ Hillier S, Ferris D, Fine D, Ferrieri P, et al. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III [Presentation]. Annual meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania; October 20–November 1, 2009.
  5. ↑ Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.CDC.gov

Template:Bacterial diseases


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]